ClinConnect ClinConnect Logo
Search / Trial NCT06907797

Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing

Launched by DANA-FARBER CANCER INSTITUTE · Mar 26, 2025

Trial Information

Current as of July 24, 2025

Recruiting

Keywords

Acute Leukemia Leukemia

ClinConnect Summary

The Tools for Reducing Inequity in Acute Leukemia (TRIAL) study is testing a new web-based application designed to help people diagnosed with acute leukemia. This application provides important information and resources about leukemia and how to participate in clinical trials, which are research studies that help find better treatments. The goal of the trial is to see how effective this tool can be in supporting patients during their treatment journey.

To be eligible for this study, participants need to be 18 years or older, speak English, and be suspected of having acute leukemia. They must also be admitted to a specific hospital unit for treatment. Participants should be able to understand and sign a consent form, which means they agree to take part in the study. Those with serious cognitive issues that prevent them from participating, or those who have already taken part in earlier testing of the application, will not be included. If you join, you can expect to help test the application in person and provide feedback on its usefulness. This is an important step in ensuring that patients have the tools they need to navigate their diagnosis and treatment effectively.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age 18 or older
  • English speaking
  • Ability to understand and willingness to sign written informed consent
  • Clinical suspicion of acute leukemia
  • Admitted to DFCI-affiliated inpatient unit
  • Exclusion Criteria:
  • Cognitive impairment rendering the individual unable to participate in beta testing
  • This will be assessed by focused chart review and consultation with the patients' inpatient care team.
  • The following populations will be excluded: adults unable to consent, individuals who are not yet adults (infants, children, teenagers \<18 years old), prisoners.
  • Inability to participate in in-person application testing.
  • Patients who participated in alpha-testing through protocol 23-404 (Appendix A)

About Dana Farber Cancer Institute

The Dana-Farber Cancer Institute is a premier cancer research and treatment institution located in Boston, Massachusetts. Renowned for its commitment to advancing cancer care through innovative research, the institute integrates cutting-edge clinical trials with a multidisciplinary approach to patient care. With a focus on translating scientific discoveries into effective therapies, Dana-Farber collaborates with a network of leading researchers and healthcare professionals to improve outcomes for patients with cancer. The institute’s dedication to education, advocacy, and community engagement further underscores its mission to eradicate cancer and enhance the quality of life for those affected by the disease.

Locations

Boston, Massachusetts, United States

Patients applied

0 patients applied

Trial Officials

Andrew Hantel, MD

Principal Investigator

Dana-Farber Cancer Institute

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported